$TVGN News

UPDATE – Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC

Tevogen Signs Letter Of Intent To Evaluate A Potential Transaction With HRK Healthcare; Sees Path To Realizing ~$100M In Combined Annual Revenue

Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements

Tevogen Bio Holdings Inc. Becomes Tevogen Inc.

Tevogen To Operate Under Tevogen Inc. Name, Effective July 30

Tevogen Bio Announces 2026 Annual Meeting of Stockholders

Tevogen Announces Formation of a Healthcare Services Initiative

Tevogen Creates Healthcare Services Initiative Led By VP Of Strategic Initiatives William Keane On Interim Basis

Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization

Letter to Shareholders from CEO Dr. Ryan Saadi

Tevogen Bio Holdings Q1 EPS $(1.61) Beats $(2.50) Estimate

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

Tevogen Enters $3M Private Placement PIPE Financing At $8.00/Prefunded Warrant, Issuing 375K Warrants Each Exercisable For The Purchase Of 1 Share Of The Company's Common Stock

Tevogen (TVGN) Soars 11% as Firm Gears Up for AI Training Commercialization

Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

Tevogen Bio Eyes Acquisition Of Global CRO To Add $20M+ Revenue And Fuel Growth Across Oncology, Rare Diseases, And Medical Devices

Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement